Trial Profile
A Phase 2a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-4482 in Healthy Participants Inoculated With Experimental Respiratory Syncytial Virus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Molnupiravir (Primary)
- Indications Chikungunya virus infections; COVID 2019 infections; Eastern equine encephalomyelitis; Ebola virus infections; Influenza virus infections; Middle East respiratory syndrome coronavirus; Renal failure; Respiratory syncytial virus infections; Severe acute respiratory syndrome; Venezuelan equine encephalomyelitis
- Focus Therapeutic Use
- Acronyms MK-4482-017
- Sponsors Merck Sharp & Dohme Corp.
- 17 May 2023 Status changed from active, no longer recruiting to completed.
- 11 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Mar 2023 Planned primary completion date changed from 22 Apr 2023 to 20 Apr 2023.